Merus N.V. has 9 Schedule 13D or 13G filings on record since 2025-08-12. No holder's latest filing reports 5% or more. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Commodore Capital LP | 4.7% | 3,525,000 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Fmr LLC | 3.7% | 2,782,935 | SCHEDULE 13G/A, 2025-11-05 | 2025-09-30 |
| RTW Investments, LP | 2.7% | 2,025,277 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Wellington Management Group LLP | 0.6% | 459,087 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 |
| Paradigm BioCapital Advisors LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Genmab A/S | 0% | 0 | SCHEDULE 13D/A, 2025-12-30 | 2025-12-30 |
Purpose of Transaction (Item 4)
Genmab A/S
Item 4 of the Schedule 13D is amended and restated in its entirety as follows: "The purpose of the transactions described in this Schedule 13D is for the Reporting Persons to acquire control of all of the issued and outstanding Common Shares of the Issuer while allowing all of the Issuer's shareholders an opportunity to receive the purchase price of $97.00 per Common Share by tendering their Common Shares pursuant to the Offer. At 5:00 p.m. New York City time on December 29, 2025, the Subsequent Offering Period expired. The Common Shares ceased to trade on Nasdaq prior to the opening of trading on December 30, 2025, and Nasdaq has filed with the SEC a Notification of Removal from Listing and/or Registration under Section 12(b) of the Exchange Act on Form 25 to delist the Common Shares from Nasdaq and deregister the Common Shares under Section 12(b) of the Exchange Act. In addition, after the Form 25 becomes effective, Purchaser intends to cause the Issuer to file with the SEC a Certification and Notice of Termination of Registration on Form 15 and take steps to cause the suspension of all of the Issuer's reporting obligations to the SEC with respect to the Common Shares. The information set forth in the section of the Offer to Purchase entitled "Summary Term Sheet" and "Purpose of the Offer; Back-End Transactions; Plans for Merus" is incorporated herein by reference. The foregoing summary is qualified in its entirety by the full text of the Offer to Purchase, which are …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-12-30; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-12 | Wellington Management Group LLP | 5% | SCHEDULE 13G/A |
| 2025-08-14 | Commodore Capital LP | 4.7% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 3.7% | SCHEDULE 13G/A |
| 2025-11-12 | Wellington Management Group LLP | 0.6% | SCHEDULE 13G/A |
| 2025-11-14 | Paradigm BioCapital Advisors LP | 6.2% | SCHEDULE 13G/A |
| 2025-11-14 | RTW Investments, LP | 2.7% | SCHEDULE 13G/A |
| 2025-12-19 | Genmab A/S | 94.8% | SCHEDULE 13D |
| 2025-12-30 | Genmab A/S | 0% | SCHEDULE 13D/A |
| 2026-02-17 | Paradigm BioCapital Advisors LP | 0% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Merus N.V.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.